312 related articles for article (PubMed ID: 24754973)
1. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
Billes SK; Sinnayah P; Cowley MA
Pharmacol Res; 2014 Jun; 84():1-11. PubMed ID: 24754973
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with naltrexone and bupropion for obesity.
Billes SK; Greenway FL
Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
[TBL] [Abstract][Full Text] [Related]
3. Naltrexone for the treatment of obesity: review and update.
Lee MW; Fujioka K
Expert Opin Pharmacother; 2009 Aug; 10(11):1841-5. PubMed ID: 19537999
[TBL] [Abstract][Full Text] [Related]
4. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
[TBL] [Abstract][Full Text] [Related]
5. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
Padwal R
Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
[TBL] [Abstract][Full Text] [Related]
6. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Guerdjikova AI; Walsh B; Shan K; Halseth AE; Dunayevich E; McElroy SL
Adv Ther; 2017 Oct; 34(10):2307-2315. PubMed ID: 28918581
[TBL] [Abstract][Full Text] [Related]
8. Rational design of a combination medication for the treatment of obesity.
Greenway FL; Whitehouse MJ; Guttadauria M; Anderson JW; Atkinson RL; Fujioka K; Gadde KM; Gupta AK; O'Neil P; Schumacher D; Smith D; Dunayevich E; Tollefson GD; Weber E; Cowley MA
Obesity (Silver Spring); 2009 Jan; 17(1):30-9. PubMed ID: 18997675
[TBL] [Abstract][Full Text] [Related]
9. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Halseth A; Shan K; Walsh B; Gilder K; Fujioka K
Obesity (Silver Spring); 2017 Feb; 25(2):338-345. PubMed ID: 28026920
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
Smith SR; Fujioka K; Gupta AK; Billes SK; Burns C; Kim D; Dunayevich E; Greenway FL
Diabetes Obes Metab; 2013 Sep; 15(9):863-6. PubMed ID: 23489381
[TBL] [Abstract][Full Text] [Related]
11. Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample.
Dalton M; Finlayson G; Walsh B; Halseth AE; Duarte C; Blundell JE
Int J Obes (Lond); 2017 Aug; 41(8):1232-1236. PubMed ID: 28373674
[TBL] [Abstract][Full Text] [Related]
12. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
13. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
Fujioka K; Plodkowski R; O'Neil PM; Gilder K; Walsh B; Greenway FL
Int J Obes (Lond); 2016 Sep; 40(9):1369-75. PubMed ID: 27328752
[TBL] [Abstract][Full Text] [Related]
14. Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.
Clapper JR; Athanacio J; Wittmer C; Griffin PS; D'Souza L; Parkes DG; Roth JD
Eur J Pharmacol; 2013 Jan; 698(1-3):292-8. PubMed ID: 23178527
[TBL] [Abstract][Full Text] [Related]
15. ACS chemical neuroscience molecule spotlight on contrave.
Mercer SL
ACS Chem Neurosci; 2011 Sep; 2(9):484-6. PubMed ID: 22860172
[TBL] [Abstract][Full Text] [Related]
16. Contrave--a combination of bupropion and naltrexone for weight loss.
Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
[No Abstract] [Full Text] [Related]
17. Drug treatment of obesity.
Bray GA; Ryan DH
Psychiatr Clin North Am; 2011 Dec; 34(4):871-80. PubMed ID: 22098810
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Apovian CM
Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update.
Christou GA; Kiortsis DN
Hormones (Athens); 2015; 14(3):370-5. PubMed ID: 26188223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
